Search

Your search keyword '"Chang, David W."' showing total 1,012 results
Start Over Author "Chang, David W." Publication Year Range Last 50 years
1,012 results on '"Chang, David W."'

5. Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma

Author

Deng, Yang, Tu, Huakang, Pierzynski, Jeanne A, Miller, Ethan D, Gu, Xiangjun, Huang, Maosheng, Chang, David W, Ye, Yuanqing, Hildebrandt, Michelle AT, Klein, Alison P, Zhao, Ren, Lippman, Scott M, and Wu, Xifeng

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Digestive Diseases, Prevention, Rare Diseases, Clinical Research, Pancreatic Cancer, Good Health and Well Being, Adult, Black or African American, Age Factors, Aged, Aged, 80 and over, Carcinoma, Pancreatic Ductal, Comorbidity, Educational Status, Female, Health Status, Hispanic or Latino, Humans, Kaplan-Meier Estimate, Life Style, Logistic Models, Male, Mental Health, Middle Aged, Multivariate Analysis, Neoplasm Staging, Odds Ratio, Pancreatic Neoplasms, Proportional Hazards Models, Quality of Life, Risk Factors, Sex Factors, Surveys and Questionnaires, United States, White People, Quality of life, Pancreatic ductal adenocarcinoma, Overall survival, Prognostic indicator, Short Form-12, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundQuality of life (QOL) is impaired in pancreatic cancer patients. Our aim was to investigate the determinants and prognostic value of QOL after diagnosis in a hospital-based cohort of racially/ethnically diverse patients with pancreatic ductal adenocarcinoma (PDAC).Patients and methodsQOL was prospectively assessed using the Short Form-12 in 2478 PDAC patients. The Physical Component Summary (PCS) and Mental Component Summary (MCS) were categorised into tertiles based on their distribution. Ordered logistic regression was adopted to compare the risk of having lower PCS and MCS by patient sociodemographic and clinical characteristics. The association of PCS and MCS with mortality was assessed by Cox regression.ResultsCompared with non-Hispanic whites, Hispanics were at significantly higher risk of having lower PCS (odds ratio [95% CI], 1.69 [1.26-2.26]; P

Published
2018

9. Preface

Author

Cheng, Ming-Huei, primary, Chang, David W., additional, and Patel, Ketan M., additional

Published
2022
Full Text
View/download PDF

12. List of Contributors

Author

Anbari, Allison Brandt, primary, Anderson, Elizabeth A., additional, Armer, Jane M., additional, Bernas, Michael, additional, Boccardo Jr, Francesco, additional, Bravo, Miguel G., additional, Brorson, Håkan, additional, Brussaard, Carola, additional, Campisi, Corradino, additional, Campisi, Corrado Cesare, additional, Chang, David W., additional, Chang, Edward I., additional, Chang, Jeff, additional, Chao, Albert H., additional, Chen, Hung-Chi, additional, Cheng, Ming-Huei, additional, Constantine, Thomas, additional, Coriddi, Michelle, additional, Cromwell, Kate D., additional, Dayan, Joseph H., additional, Feldman, Joseph L., additional, Gould, Daniel J., additional, Inchauste, Suzanne M., additional, Jackson, Katherine A., additional, Johnson, Anna Rose, additional, Kataru, Raghu P., additional, Koshima, Isao, additional, Liu, Tiffany Ting-Fong, additional, Maruccia, Michele, additional, Mehrara, Babak J., additional, Nguyen, Alexander T., additional, Nguyen, Dung H., additional, Pappalardo, Marco, additional, Patel, Ketan M., additional, Ryan, Melissa, additional, Shinaoka, Akira, additional, Singhal, Dhruv, additional, Skoracki, Roman J., additional, Smith, Mark L., additional, Suami, Hiroo, additional, Sun, Yuanlu, additional, Tidhar, Dorit, additional, Wareg, Nuha K., additional, Yamamoto, Takumi, additional, Yamashita, Shuji, additional, Yildirim, Mehmet Emin Cem, additional, and Zeltzer, Assaf, additional

Published
2022
Full Text
View/download PDF

19. Inflammation‐Related Genetic Variations and Survival in Patients With Advanced Non–Small Cell Lung Cancer Receiving First‐Line Chemotherapy

Author

Pu, Xia, Hildebrandt, Michelle A, Lu, Charles, Roth, Jack A, Stewart, David J, Zhao, Yang, Heist, Rebecca S, Ye, Yuanqing, Chang, David W, Su, Li, Minna, John D, Lippman, Scott M, Spitz, Margaret R, Christiani, David C, and Wu, Xifeng

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Lung, Human Genome, Genetics, Lung Cancer, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Aged, Antineoplastic Combined Chemotherapy Protocols, Boston, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, Female, Genotype, HLA-D Antigens, Humans, Inflammation, Kaplan-Meier Estimate, Lung Neoplasms, Male, Middle Aged, NK Cell Lectin-Like Receptor Subfamily K, Neoplasm Staging, Phenotype, Polymorphism, Single Nucleotide, Proportional Hazards Models, Risk Factors, Texas, Time Factors, Treatment Outcome, Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy, Pharmacology and pharmaceutical sciences
Abstract

Accurate prognostic prediction is challenging for patients with advanced-stage non-small cell lung cancer (NSCLC). We systematically investigated genetic variants within inflammation pathways as potential prognostic markers for advanced-stage NSCLC patients treated with first-line chemotherapy. A discovery phase in 502 patients and an internal validation phase in 335 patients were completed at the MD Anderson Cancer Center. External validation was performed in 371 patients at Harvard University. A missense single-nucleotide polymorphism (SNP) in the gene encoding the major histocompatibility complex class II, DO-β chain (HLA-DOB:rs2071554), predicted to influence protein function, was significantly associated with poor survival in the discovery (hazard ratio (HR): 1.46; 95% confidence interval (CI): 1.02-2.09), internal validation (HR: 1.51; 95% CI: 1.02-2.25), and external validation (HR: 1.52; 95% CI: 1.01-2.29) populations. KLRK1:rs2900420 was associated with reduced risk in the discovery (HR: 0.76; 95% CI: 0.60-0.96), internal validation (HR: 0.77; 95% CI: 0.61-0.99), and external validation (HR: 0.80; 95% CI: 0.63-1.02) populations. A strong cumulative effect on overall survival was observed for these SNPs. Genetic variations in inflammation-related genes could have potential to complement prediction of prognosis.

Published
2014

30. Supplementary Table 1 from Multistage Analysis of Variants in the Inflammation Pathway and Lung Cancer Risk in Smokers

Author

Spitz, Margaret R., primary, Gorlov, Ivan P., primary, Dong, Qiong, primary, Wu, Xifeng, primary, Chen, Wei, primary, Chang, David W., primary, Etzel, Carol J., primary, Caporaso, Neil E., primary, Zhao, Yang, primary, Christiani, David C., primary, Brennan, Paul, primary, Albanes, Demetrius, primary, Shi, Jianxin, primary, Thun, Michael, primary, Landi, Maria Teresa, primary, and Amos, Christopher I., primary

Published
2023
Full Text
View/download PDF

32. Data from Multistage Analysis of Variants in the Inflammation Pathway and Lung Cancer Risk in Smokers

Author

Spitz, Margaret R., primary, Gorlov, Ivan P., primary, Dong, Qiong, primary, Wu, Xifeng, primary, Chen, Wei, primary, Chang, David W., primary, Etzel, Carol J., primary, Caporaso, Neil E., primary, Zhao, Yang, primary, Christiani, David C., primary, Brennan, Paul, primary, Albanes, Demetrius, primary, Shi, Jianxin, primary, Thun, Michael, primary, Landi, Maria Teresa, primary, and Amos, Christopher I., primary

Published
2023
Full Text
View/download PDF

34. Data from Genome-Wide Association Study of Genetic Predictors of Overall Survival for Non–Small Cell Lung Cancer in Never Smokers

Author

Wu, Xifeng, primary, Wang, Liang, primary, Ye, Yuanqing, primary, Aakre, Jeremiah A., primary, Pu, Xia, primary, Chang, Gee-Chen, primary, Yang, Pan-Chyr, primary, Roth, Jack A., primary, Marks, Randolph S., primary, Lippman, Scott M., primary, Chang, Joe Y., primary, Lu, Charles, primary, Deschamps, Claude, primary, Su, Wu-Chou, primary, Wang, Wen-Chang, primary, Huang, Ming-Shyan, primary, Chang, David W., primary, Li, Yan, primary, Pankratz, V. Shane, primary, Minna, John D., primary, Hong, Waun Ki, primary, Hildebrandt, Michelle A.T., primary, Hsiung, Chao Agnes, primary, and Yang, Ping, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 2 from Genome-Wide Association Study of Genetic Predictors of Overall Survival for Non–Small Cell Lung Cancer in Never Smokers

Author

Wu, Xifeng, primary, Wang, Liang, primary, Ye, Yuanqing, primary, Aakre, Jeremiah A., primary, Pu, Xia, primary, Chang, Gee-Chen, primary, Yang, Pan-Chyr, primary, Roth, Jack A., primary, Marks, Randolph S., primary, Lippman, Scott M., primary, Chang, Joe Y., primary, Lu, Charles, primary, Deschamps, Claude, primary, Su, Wu-Chou, primary, Wang, Wen-Chang, primary, Huang, Ming-Shyan, primary, Chang, David W., primary, Li, Yan, primary, Pankratz, V. Shane, primary, Minna, John D., primary, Hong, Waun Ki, primary, Hildebrandt, Michelle A.T., primary, Hsiung, Chao Agnes, primary, and Yang, Ping, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from Genome-Wide Association Study of Genetic Predictors of Overall Survival for Non–Small Cell Lung Cancer in Never Smokers

Author

Wu, Xifeng, primary, Wang, Liang, primary, Ye, Yuanqing, primary, Aakre, Jeremiah A., primary, Pu, Xia, primary, Chang, Gee-Chen, primary, Yang, Pan-Chyr, primary, Roth, Jack A., primary, Marks, Randolph S., primary, Lippman, Scott M., primary, Chang, Joe Y., primary, Lu, Charles, primary, Deschamps, Claude, primary, Su, Wu-Chou, primary, Wang, Wen-Chang, primary, Huang, Ming-Shyan, primary, Chang, David W., primary, Li, Yan, primary, Pankratz, V. Shane, primary, Minna, John D., primary, Hong, Waun Ki, primary, Hildebrandt, Michelle A.T., primary, Hsiung, Chao Agnes, primary, and Yang, Ping, primary

Published
2023
Full Text
View/download PDF

45. Advances in surgical treatment of lymphedema

Author

Beederman, Maureen and Chang, David W.

Subjects
Microsurgery, medicine.medical_specialty, RD1-811, business.industry, General surgery, medicine.medical_treatment, Advances, Review Article, medicine.disease, Debulking, humanities, Imaging modalities, Treatment, body regions, Lymphedema, Extremity/Lymphedema, hemic and lymphatic diseases, medicine, Surgery, Surgical treatment, business
Abstract

An estimated 250 million people worldwide suffer from lymphedema. In the past, the firstline option for treatment was nonsurgical management, either in the form of compression garments or wrapping, or comprehensive decongestive therapy, with debulking surgery reserved for the more advanced cases. However, with improvements in microsurgical techniques and imaging modalities, surgical intervention is increasingly being utilized. This review highlights recent advancements in the surgical treatment of lymphedema, specifically focusing on improvements in imaging, surgical techniques, and prevention of lymphedema.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results